FSH Signaling Pathway in Oncology Drug Pipeline Update
|出版商||BioSeeker Group AB||商品編碼||232962|
Follicle stimulating hormone (FSH) binds to FSH-receptor which is coupled to Gs protein that in turn activates cAMP dependent protein kinases (PKA) and thus triggers FSH signaling which continues further downstream. Activation of PKA leads to phosphorylation of transcription factors like cAMP response element binding protein(CREB) and brings about chromatin remodeling by phosphorylating histone H3. It also enhances the activity of the p38 MAPK, ERK, and PI3K signaling cascades. FSH majorly induces steroidogenesis and is involved in the normal growth and function of reproductive organs in mammals.
There are today 273 companies plus partners developing 369 FSH pathway targeting drugs in 1441 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 167 drugs. Fsh Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 165 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 164 out of the 164 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 39 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug name & Synonyms
Target Expression Profile
Principal Company & Partners
Target and Molecular Function of Target
Fillings and Approvals
Phase IV Data
Phase III Data
Phase II Data
Phase I Data
Phase 0 Data
Dynamic Report Generator